WO2000042194A2 - Mutant hepatitis b surface antigen and testing - Google Patents
Mutant hepatitis b surface antigen and testing Download PDFInfo
- Publication number
- WO2000042194A2 WO2000042194A2 PCT/GB2000/000107 GB0000107W WO0042194A2 WO 2000042194 A2 WO2000042194 A2 WO 2000042194A2 GB 0000107 W GB0000107 W GB 0000107W WO 0042194 A2 WO0042194 A2 WO 0042194A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- neg
- hepatitis
- hbsag
- antigen
- amino acid
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 35
- 108091007433 antigens Proteins 0.000 title claims abstract description 35
- 102000036639 antigens Human genes 0.000 title claims abstract description 35
- 238000012360 testing method Methods 0.000 title description 8
- 208000006454 hepatitis Diseases 0.000 title description 2
- 231100000283 hepatitis Toxicity 0.000 title description 2
- 150000001413 amino acids Chemical class 0.000 claims abstract description 26
- 208000002672 hepatitis B Diseases 0.000 claims abstract description 17
- 229960005486 vaccine Drugs 0.000 claims abstract description 7
- 238000003556 assay Methods 0.000 claims description 46
- 108091033319 polynucleotide Proteins 0.000 claims description 4
- 102000040430 polynucleotide Human genes 0.000 claims description 4
- 239000002157 polynucleotide Substances 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- 239000007791 liquid phase Substances 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- 238000011282 treatment Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 4
- 238000007423 screening assay Methods 0.000 abstract description 3
- 230000009257 reactivity Effects 0.000 description 24
- 241000700721 Hepatitis B virus Species 0.000 description 23
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 229940024606 amino acid Drugs 0.000 description 11
- 238000001514 detection method Methods 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 241000283707 Capra Species 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 230000035772 mutation Effects 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 241000700199 Cavia porcellus Species 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 238000010166 immunofluorescence Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 101100191372 Arabidopsis thaliana PRK5 gene Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000581002 Murex Species 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000027645 antigenic variation Effects 0.000 description 3
- OJYGBLRPYBAHRT-IPQSZEQASA-N chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]21 OJYGBLRPYBAHRT-IPQSZEQASA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 102200050844 rs386833793 Human genes 0.000 description 3
- 102220059798 rs56203955 Human genes 0.000 description 3
- 102220018931 rs80358540 Human genes 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 101100026203 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) neg-1 gene Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 101150010882 S gene Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 101710147732 Small envelope protein Proteins 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000002820 assay format Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 229940036107 hepatitis b immunoglobulin Drugs 0.000 description 2
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 2
- 229940124736 hepatitis-B vaccine Drugs 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229940021993 prophylactic vaccine Drugs 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 102220110169 rs182216711 Human genes 0.000 description 2
- 102220275113 rs763707922 Human genes 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- LOLNFJHUEIDGNH-PIXDULNESA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-[(e)-2-iodoethenyl]pyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\I)=C1 LOLNFJHUEIDGNH-PIXDULNESA-N 0.000 description 1
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- 206010059193 Acute hepatitis B Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101710142246 External core antigen Proteins 0.000 description 1
- 108700024845 Hepatitis B virus P Proteins 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 208000037628 acute hepatitis B virus infection Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229960004396 famciclovir Drugs 0.000 description 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
- 239000012909 foetal bovine serum Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 102220230382 rs890297188 Human genes 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- the present invention relates to a mutant hepatitis B surface antigen (HBsAg), and to monoclonal and polyclonal antibodies raised against the antigen, which exhibit an ability to detect a wide variety of hepatitis B virus (HBV) strains and antigenic variations. As such, it is particularly useful as the basis of a screening assay.
- the antigen may also be useful as a therapeutic (or prophylactic) vaccine.
- HBsAg surface antigen
- HBsAg variants can be divided into 2 aetiological classes. The first class occurs naturally and includes subtype variation and amino acid (aa) changes which may be poorly detected in diagnostic assays. Class 2 variants are selected by medically induced immune pressure, for example after vaccination and/or treatment with hepatitis B immunoglobulin (HBIG) (3,4). Class 2 antigenic variation tends to occur within the proposed neutralising epitopes but both classes show variation in the clusters of epitopes which constitute the external domain, referred to as the major hydrophillic region (MHR) of HBsAg
- MHR major hydrophillic region
- HBsAg negative sera are associated with variants of HBsAg that are not detectable by some commercial assays (10.1 1), but most appear to be due to the levels of HBsAg being below the level of detection. PCR is useful in differentiating between these two situations ( 16).
- She was HBsAg negative, but had antibodies to HBsAg (anti-HBs) and anti-HBc positive; usually this combination indicates past infection.
- the invention also concerns therapy for HBV infection.
- Interferon ⁇ IFN
- the only drug licensed in the UK to treat HBV. is effective in only a third of those treated.
- the fundamental problem with chronic HBV is an ineffective HBV-specific immune response.
- HBV-specific vaccines led to complete down regulation of mRNA synthesis from the transgene by a post-transcriptional mechanism 9 .
- An object of the invention is to mitigate these problems.
- the present invention provides a mutant hepatitis B surface antigen (HBsAg), which comprises wild type HBsAg having the following amino acid changes : Position Amino Acid (Wild Type)
- the mutant antigen having the four previously unknown amino acid changes at positions 30, 98. 101 and 210 is particularly preferred. Mutations at positions 3 and 53 have been noted previously in other strains. Of 1 13 hepatitis B surface antigen strains available from Norder (reference 18) and from Genbank (sequence database). 21 have S (serine) at amino acid position 3. the remainder have N (asparagine). At amino acid position 53, L (leucine) is present in 5 of the 1 13 strains only. N3S and S53L in combination are present in only 2 out of 1 13 strains.
- the antigen may also have other sequence changes relative to the wild type at other positions provided that the antigenicity of the antigen of the present invention is substantially unaffected.
- the invention is based on the surprising finding that the mutant antigen is detected in all commercial immunoassays (employing immobilised antibodies from a variety of sources) tested, with a reactivity which was generally as good as and in some cases better than either of the hepatitis B wild types tested. The antigen bound to all monoclonal antibodies tested.
- the mutant antigen therefore has utility in the production of monoclonal or polyclonal antibodies (possibly in higher titre than hitherto) having the ability to detect a wide variety of hepatitis B variants, and thus form the basis of a more complete type-independent screening assay.
- the invention extends to such monoclonal or polyclonal antibodies.
- the invention also relates to an immunoassay device wherein an antigen or antibody according to the present invention is immobilised on a solid substrate.
- assay formats are known in the art. including solid substrates in the form of glass or plastic surfaces (such as microtitre plates), polymer beads or sticks. Alternatively, in more recent assay formats the antigen or antibody is first present in a liquid phase, where an initial reaction step occurs.
- the antibodies may also carry a detectable label, such as a radiolabel, fluorescence label, enzyme label or other label known in the art.
- a detectable label such as a radiolabel, fluorescence label, enzyme label or other label known in the art.
- the labelled antibodies may be used to detect or visualise antigen from a test sample which has been captured by immobilised antibody in an immunoassay device.
- the invention also extends to polynucleotide coding for the mutant antigen and which may be used to clone the antigen in a suitable expression system.
- the invention also relates to the use of the antigen as a therapeutic or prophylactic vaccine.
- Post-infection therapeutic vaccination is believed to be effective in stimulating the immune system (particularly T-cells) and thereby clearing virus from infected patients.
- the present antigen would stimulate a wide range of antibodies, which would bind to and so protect against a variety of variant antigens.
- the antigen of the present invention may be formulated as a vaccine according to known techniques, including for example adjuvants such as aluminium hydroxide etc. The range of immune responses generated is beneficial.
- HBsAg negative but anti-HBs and anti-HBc positive came from a female bone marrow transplant (BMT) donor, who was HBsAg negative but anti-HBs and anti-HBc positive. She was found to have four unique amino acid substitutions at positions 30, 98, 101 and 210 of the S gene. However, surprisingly, in vitro expressed HBsAg from the donor was detected by commercial kits at a similar or higher level than a standard sequence. Binding to monoclonal anti-HBs antibodies
- wild type sequences GlyY and GlyD themselves differ in amino acids at least at positions 122 and 160.
- mutations are indicated as, for example, N3S; which indicates that normal amino acid N at position 3 is replaced by S in the mutant.
- Hepatitis B serological markers HBsAg (Auszyme; monoclonal based), anti-HBs, HBeAg, anti-HBe, anti-HCV (EIA II), a ⁇ ti-HDV and anti-HIV were all tested using commercially available enzyme immunoassays (Abbott Laboratories, North Chicago, IL. HBsAg was also tested by a polyclonal anti-HBs based assay (Murex, Dartford, UK).
- Serum is rarely available in volumes sufficient for test against a multitude of capture antibodies, therefore we cloned variant HBsAg and obtained a significant quantity of protein using a mammalian expression system.
- HBV DNA was extracted from 50 ⁇ l of serum using the QIAamp Blood Kit (QIAGEN, Crawley, UK) according to the manufacturer's instructions.
- QIAamp Blood Kit QIAGEN, Crawley, UK
- a hot-start, nested polymerase chain reaction PCR was performed to amplify the surface (S) gene.
- Five microliters of extracted DNA was amplified in a 50 ⁇ l solution containing 1U Taq polymerase
- the S6C and S7D primers used in the nested PCR incorporate restriction sites for EcoRl and Hindlll respectively.
- the purified PCR product was ligated into the mammalian expression vector pRK5 using these restriction sites and transformed into the E.coli strain DH5 ⁇ .
- Plasmid DNA was purified using a Qiagen plasmid midi-kit (QIAGEN, Crawley, UK) and fluorescence-based sequencing of the whole surface gene was carried out using the ABI PRISM Ready Reaction dRhodamine Terminator Cycle Sequencing Kit (Perkin Elmer, Cheshire, UK) according to the manufacturer's instructions.
- the primers used for sequencing were S6C and S7D with the internal primers S3 [S'-AATGGCACTAGTAAACTGAGCC-S'J, S4 [5 ' -GTATGTTGCCCGTTTGTCCTC-3'j and S8 [5'-AGAAGATGAGGCATAGCAGC- 3 * ]. Sequence analysis was performed with the GCG programme (Wisconsin sequence analysis package, version 9.1. Genetics Computer Group, Madison, Wise.) (iv) Expression of BsAg
- the plasmid. with its entire HBV surface gene insert was transfected into subconfluent monolayers of COS7 cells on 16mm coverslips using either cationic liposomes, made from dioleoyl L- -phosphatidyl ethanolamine and dimethyldioctadecyl ammonium bromide (Sigma-Aldrich. Dorset. UK) (6,7). or the standard calcium phosphate method. Briefly, l ⁇ g plasmid was diluted in 50 ⁇ l Optimem 1 reduced serum medium (Life Technologies. Paisley, UK) and. in a separate vial. 7 ⁇ l of liposomes was added to 50 ⁇ l of Optimem 1.
- the two solutions were mixed and allowed to stand for 15 min at room temperature, then further diluted with 500 ⁇ l of Optimem 1 and added to pre-washed COS7 cells.
- the cells were incubated with the transfection mixture for 5h at 37°C in 5% CO2 and then 500 ⁇ l of COS7 medium added (Dulbeccos MEM Medium with 5% foetal bovine serum, 0.02 IU/ml Penicillin, 0.02 ⁇ l/ml Streptomycin and 4 ⁇ M L-Glutamine. All Life Technologies, Paisley, UK). Cells were incubated for 16h at 37°C in 5% CO2 when the transfection mixture was removed and 2ml of fresh COS7 medium added.
- COS7 medium Dulbeccos MEM Medium with 5% foetal bovine serum, 0.02 IU/ml Penicillin, 0.02 ⁇ l/ml Streptomycin and 4 ⁇ M L-Glutamine. All Life Technologies, Paisley, UK.
- Plasmid pRK5 containing standard HBV DNA S gene sequence (both adw and ayw subtypes) was used as a control for transfection and antigenic analysis. After 2 days, the culture medium was harvested and coverslips collected for immunofluorescence.
- the assays employed were - [1] bioELISA HBsAg colour. BIOKIT, Longfield, Kent, UK; [2JAUSRIA 11-125, Abbott Laboratories Ltd., Maidenhead. UK; [3] VIDAS HBsAg, bioMerieux SA. Marcy Etoile, France; [4]Enzymun-Test HBsAg ES300, Boehringer Mannheim GmbH. Mannheim.
- COS7 cells on coverslips were methanol fixed, washed with phosphate-buffered saline (PBS) and incubated with goat anti-HBsAg polyclonal antibody (pAb) (Dako, High Wycombe, UK) for 45 min at room temperature. After washing, the cells were incubated with the secondary antibody, anti-goat fluorescein isothiocyanate (FITC) labelled immunoglobulin (IgG), for 30 min at room temperature (Sigma- Aldrich Company, Dorset, UK). Cells were examined under a Nikon Microphot-SA microscope.
- PBS phosphate-buffered saline
- pAb goat anti-HBsAg polyclonal antibody
- FITC anti-goat fluorescein isothiocyanate
- IgG immunoglobulin
- Monoclonal and polyclonal antibodies may be produced and labelled using conventional techniques as described, for example, in: 1. "Antibodies - a laboratory manual”. Ed Harlow and David Lane, 1988
- the variants, origin and clinical background of each sample is detailed in Table 1.
- the donor sequence that forms the basis of this application had 6 amino acid substitutions as compared with the sequence of an adr prototype [20]: N3S, Q30R, S53L, L98V, Q101R, and S210T.
- Q30R, L98V, Q101R and S210T present in the donor were not seen in the complete amino acid sequence of HBsAg from 88 HBV strains [18].
- Figure 1 is the BMT amino acid sequence according to the present invention
- Figure 2 compares the BMT sequence to the wild type (adr subtype) sequence
- Figure 3 is the BMT nucleic acid sequence.
- the diagnostic reactivity of the expressed HBsAg (Table 2) can be divided into three groups; those which displayed high reactivity in most assays, those with intermediate reactivity and those with poor reactivity.
- the first group includes samples GlyD and Gly Y (positive controls containing expressed HBsAg of standard sequence), 91-4696, BMT, AP3.1,
- SA6 and SA7 which displayed mutations in HBs regions 1, 3 and 4 of the MHR (1,2). Samples SA6 and SA7 displayed high reactivity in 5 assays and reduced reactivity in 2 assays.
- Argl45. M5. 1056Sp, BA2.4, BA 3.4 and SA4 in the intermediate group were reactive in several assays but at a reduced level. Some of these samples displayed low level reactivity in certain assays : Argl45 was low in assays 2. 3 and 6 and negative in assay 7; M5 was negative in assays 3, 4, 6 and 7; 1056Sp. and BA2.4 were negative in assays 4 and 7; BA3.4 was negative in assays 3 and 5.
- This intermediate group contained mutations scattered across the entire MHR.
- mAb for detection
- assays 5 and 6 picked up 10.
- the two assays which employed mouse mAb for both capture and detection detected 9 and 8 samples respectively and the assay which detected the least number of expressed HBsAg samples (7 out of 13) was assay 7 which used sheep pAb for capture and mouse mAb for detection.
- sample BMT according to the present invention displayed similar reactivity to the standard HBV sequence (Gly D) in 4 assays (assays 1,3,6 and 7). Higher reactivity in 2 (assays 4 and 5) and slightly (but not significantly) reduced reactivity in one (assay 2).
- sample BMT according to the invention The reactivity of sample BMT according to the invention with each of the m-anti-HBs was greater than that of the standard HBV sequence (GlyD). This was not seen in any of the other variants tested (Table 5). Further it reacted with all m-anti-HBs.
- the variants seen in the BMT donor HBsAg sequence also corresponded to amino acids pN359H. pI437L. pS452C. pH470Y , pA474T, pE564D. and pS569A of the HBV polymerase gene.
- the changes at amino acids 437, 452 and 564 were not seen in the consensus sequence of the polymerase gene previously described [23] and are not those normally associated with resistance to famciclovir or lamivudine [24]. It is possible that they affect the replication competence of the virus.
- I lit working standard (0 5 IU/ml) and Ihe monitor sample (0 125 IU/ml) are solutions prepared by the National Institute of Biological Standards (I ondon UK) and distributed nationalK to diagnostic laboratories as external controls
- PRK5 (plasmid) t ( 14.5 Neg) (0.51 Neg) (0.19 Neg) (3.6 Neg) (4.1 Neg) (1 8 Neg) (5.8 Neg) COS7 cells t ( 10.9 Neg) (0.73 Neg) (0.49 Neg) (5.1 Neg) (4.2 Neg) (2-0 Neg) (6.0 Neg) WorkingStandard t 27.9 4.6 7.8 1 1.1 21.0 1 1.5 21.1
- the working standard (0.5 IU/ml) and the monitor sample (0.125 IU/ml) are solutions prepared by the National o Institute of Biological Standards (London, UK) and distributed nationally to diagnostic laboratories as external controls.
- COS7 cells 1.34 ⁇ 0.06 (8) 1.06-1.54
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00901186A EP1144646A2 (en) | 1999-01-18 | 2000-01-18 | Mutant hepatitis b surface antigen and testing |
AU21150/00A AU2115000A (en) | 1999-01-18 | 2000-01-18 | Hepatitis b testing |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9901046.4A GB9901046D0 (en) | 1999-01-18 | 1999-01-18 | Hepatitis b testing |
GB9901046.4 | 1999-01-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000042194A2 true WO2000042194A2 (en) | 2000-07-20 |
WO2000042194A3 WO2000042194A3 (en) | 2000-09-28 |
Family
ID=10846070
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2000/000107 WO2000042194A2 (en) | 1999-01-18 | 2000-01-18 | Mutant hepatitis b surface antigen and testing |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1144646A2 (en) |
AU (1) | AU2115000A (en) |
GB (1) | GB9901046D0 (en) |
WO (1) | WO2000042194A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1696040A1 (en) * | 2005-02-28 | 2006-08-30 | Eurofins Viralliance, Inc. | Method of genotyping and phenotyping hepatitis B viruses resistant to antiviral molecules |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986003975A1 (en) * | 1984-12-28 | 1986-07-17 | Japanese Foundation For Cancer Research | Hepatitis b virus vaccine and process for its preparation |
-
1999
- 1999-01-18 GB GBGB9901046.4A patent/GB9901046D0/en not_active Ceased
-
2000
- 2000-01-18 WO PCT/GB2000/000107 patent/WO2000042194A2/en not_active Application Discontinuation
- 2000-01-18 EP EP00901186A patent/EP1144646A2/en not_active Withdrawn
- 2000-01-18 AU AU21150/00A patent/AU2115000A/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986003975A1 (en) * | 1984-12-28 | 1986-07-17 | Japanese Foundation For Cancer Research | Hepatitis b virus vaccine and process for its preparation |
Non-Patent Citations (6)
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1696040A1 (en) * | 2005-02-28 | 2006-08-30 | Eurofins Viralliance, Inc. | Method of genotyping and phenotyping hepatitis B viruses resistant to antiviral molecules |
WO2006090262A1 (en) * | 2005-02-28 | 2006-08-31 | Eurofins Viralliance Inc | Method of genotyping and phenotyping hepatitis b viruses resistant to antiviral molecules |
Also Published As
Publication number | Publication date |
---|---|
AU2115000A (en) | 2000-08-01 |
GB9901046D0 (en) | 1999-03-10 |
EP1144646A2 (en) | 2001-10-17 |
WO2000042194A3 (en) | 2000-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5593825A (en) | Hepatitis B virus mutants, reagents and methods for detection | |
Hsu et al. | Surface gene mutants of hepatitis B virus in infants who develop acute or chronic infections despite immunoprophylaxis | |
Fujii et al. | Gly145 to Arg substitution in HBs antigen of immune escape mutant of hepatitis B virus | |
Tai et al. | Novel and frequent mutations of hepatitis B virus coincide with a major histocompatibility complex class I-restricted T-cell epitope of the surface antigen | |
JPH11253184A (en) | Escaped mutant of surface antigen of hepatitis b virus | |
US20070026422A1 (en) | Vaccine-induced hepatitis B viral strain and uses thereof | |
KR100370341B1 (en) | Hepatitis B Vaccine | |
Zu Putlitz et al. | Properties of monoclonal antibodies directed against hepatitis B virus polymerase protein | |
Cariani et al. | Emergence of hepatitis B virus S gene mutant in a liver transplant recipient | |
Carman et al. | Antigenic characterisation of pre-and post-liver transplant hepatitis B surface antigen sequences from patients treated with hepatitis B immune globulin | |
JP2004532019A (en) | Hepatitis B virus surface antigen variants and methods for their detection | |
Cuestas et al. | Unusual naturally occurring humoral and cellular mutated epitopes of hepatitis B virus in a chronically infected Argentine patient with anti-HBs antibodies | |
JP4866238B2 (en) | Novel surface protein (HBsAg) variant of hepatitis B virus | |
Weimer et al. | Antibodies to the RNase H domain of hepatitis B virus P protein are associated with ongoing viral replication | |
Kremsdorf et al. | Complete nucleotide sequence and viral envelope protein expression of a hepatitis B virus DNA derived from a hepatitis B surface antigen-seronegative patient | |
US8242238B2 (en) | Surface protein (HBsAg) variant of the hepatitis B virus | |
WO2000042194A2 (en) | Mutant hepatitis b surface antigen and testing | |
Yang et al. | A novel stop codon mutation in HBsAg gene identified in a hepatitis B virus strain associated with cryptogenic cirrhosis | |
US8729231B2 (en) | Surface antigen protein mutant of hepatitis B virus surface antigen | |
Coursaget et al. | Hepatitis B surface antigen reactivity in man due to a new variant of hepatitis B virus | |
Abraham et al. | Antibodies to hepatitis B virus x-protein in sera of patients with acute and chronic acitve hepatitis | |
Ireland et al. | Failed adoptive immunity transfer: reactivation or reinfection? | |
Chen et al. | Changes in the antigenicity of a hepatitis B virus mutant stemming from lamivudine therapy | |
Yong-yuan et al. | Comparison of pre-S 1 and pre-S 2 proteins in hepatocytes with replication status by in situ hybridization assay | |
Ijaz | Production and use of monoclonal antibodies against a conserved epitope of hepatitis B surface antigen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2000901186 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000901186 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09889541 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000901186 Country of ref document: EP |